N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

PrEcision Pacing in HFpEF: the PEP-HFpEF Trial

Sponsor: Tufts Medical Center • ClinicalTrials.gov ID: NCT07864558

Registry updated: 2026-10-20
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The PEP-HFpEF study is a prospective, single-center mechanistic study evaluating personalized heart rate pacing (myPACE) in patients with heart failure with preserved ejection fraction (HFpEF) and existing cardiac physiologic pacemakers. Participants will undergo sequential periods of standard and personalized pacing with serial physiologic assessments to evaluate the effects of myPACE on exercise capacity, cardiac function, biomarkers, quality of life, and clinical outcomes.

Interventions

  • Individualized myPACE pacemaker programming (Device)
    The myPACE intervention uses an individualized heart-rate algorithm to determine a personalized pacemaker backup rate within the normal range of adult resting heart rates. The algorithm estimates an individualized resting heart rate based on participant height and left ventricular ejection fraction (LVEF). The algorithm is designed to provide a modest increase in resting heart rate tailored to individual physiologic characteristics, including LVEF.

Eligibility criteria

Inclusion Criteria: * Age ≥18 years. * Diagnosis of heart failure with preserved ejection fraction (HFpEF), defined as left ventricular ejection fraction (LVEF) ≥50% with symptoms and signs consistent with heart failure as determined by the treating investigator. * New York Heart Association (NYHA) Class II or III symptoms despite stable, maximally tolerated guideline-directed medical therapy. * Pre-existing FDA-approved cardiac physiologic pacemaker (e.g., conduction system pacing or cardiac resynchronization therapy) implanted for a standard clinical indication and capable of individualized lower-rate programming. * Expected to require ongoing pacemaker therapy throughout the study period. * Clinically stable at enrollment, without recent major changes in heart failure status that, in the opinion of the investigator, would interfere with interpretation of study outcomes. * Able and willing to provide written informed consent. * Able and willing to comply with all study procedures, including pacemaker programming, cardiopulmonary exercise testing (CPET), echocardiography, blood pressure measurements, autonomic testing, blood collection, and follow-up visits. Exclusion Criteria: * Age \<18 years. * Left ventricular ejection fraction \<50%. * Pregnancy, breastfeeding, or women of childbearing potential unwilling to use an acceptable method of contraception during study participation. * Inability or unwillingness to provide informed consent. * Inability to safely perform study procedures, including CPET or autonomic testing, in the opinion of the investigator. * Any medical condition or life expectancy that, in the opinion of the investigator, would make participation unsafe or would substantially interfere with completion of the study or interpretation of study results. * Enrollment in another interventional clinical trial that, in the opinion of the investigators, could interfere with this study or confound interpretation of the results. * Prisoners, wards of the state, or other individuals for whom participation would not be permissible under applicable regulations or institutional policy.

Conditions

Heart Failure and Preserved Ejection Fraction Heart Failure New York Heart Association Class III Heart Failure New York Heart Association (NYHA) Class II

Locations

  • Tufts Medical Center — Boston, Massachusetts, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record